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VaccinedevelopmentagainsthepatitisCvirus(HCV)ishinderedbypoorunderstandingoffactorsdefining
cross-immunoreactivityamongheterogeneousepitopes.Usingsyntheticpeptidesandmouseimmunization
as a model, we conducted a quantitative analysis of cross-immunoreactivity among variants of the HCV
hypervariable region 1 (HVR1). Analysis of 26,883 immunological reactions among pairs of peptides
showedthatthedistributionofcross-immunoreactivityamongHVR1variantswasskewed,withantibodies
against a few variants reacting with all tested peptides. The HVR1 cross-immunoreactivity was accurately
modeled based on amino acid sequence alone. The tested peptides were mapped in the HVR1 sequence
space, which was visualized as a network of 11,319 sequences. The HVR1 variants with a greater network
centrality showed a broader cross-immunoreactivity. The entire sequence space is explored by each HCV
genotype and subtype. These findings indicate that HVR1 antigenic diversity is extensively convergent and
effectively limited, suggesting significant implications for vaccine development.
H
epatitis C virus (HCV) is a single-stranded RNA virus belonging to the Flaviviridae family
1. HCV infects
3.0%of theworld’spopulation andis amajor causeof liverdiseaseworldwide
2.HCVinfectionprogresses
to chronicity in 70%–85% of infected adults
3. An estimated 476,000 deaths per year are attributed to
hepatitis C
2. However, there is no vaccine against HCV and current anti-viral therapy is effective in 50%–60% of
patients
4. HCV is genetically very heterogeneous and classified into 6 genotypes and numerous subgenotypes
5.
Vaccines are among the most efficacious means to control infectious diseases. However, the development of
vaccines against highly heterogeneous viruses such as HCV and human immunodeficiency virus (HIV) is
considerably hamperedbyvariant-specific neutralizing immune responses. Theseviruseshave seeminglyunlim-
ited capacity to rapidly mutate and escape from immune neutralization, thus presenting a major obstacle for
formulating broadly protective vaccines
6,7. Considering that an estimated 130 million and 33 million individuals
are infected worldwide with HCVand HIV, respectively
2,7,and thateach infected hostharbours alarge variety of
viral variants, the number of viral variants circulating in the world is immense. Developing vaccines against such
broad range of viral variants seems a daunting task.
Classical approaches to vaccine development are yet to produce broadly protective vaccines against HCV and
HIV
6,8. Novel vaccine strategies recently developed to cope with viral antigenic diversity focus either on using
epitopes with limited heterogeneity
9,generating aconcoction of heterogeneous epitopes
10,11ormimotopes
12,13,or
predicting consensus sequences, center of tree variants or phylogenetic ancestors
14,15. These strategies are based
on specific assumptions regarding properties of highly heterogeneous epitopes, viz., that immunological specifi-
cityisstronglylinkedtotheepitopeprimarystructure,withcross-immunoreactivity(CR)decliningwithincreas-
ing genetic difference between epitopes, and that the viral sequence space is shaped by diversifying evolution
resulting from an ‘‘arms race’’
16. However, the conditional relevance of these assumptions has not been system-
atically corroborated.
ThemostimportantHCVneutralizingepitopehasbeenmappedinthehypervariableregion1(HVR1),located
at amino acid (aa) positions 384–410 in the structural protein E2. HVR1 sequence variation correlates with
neutralization escape and is associated with viral persistence during chronic infection
17–22. Although some
neutralizing epitopes have been discovered in conserved regions of HCV structural proteins
23, the variant-
specificity of humoral protective responses
24,25 points to the essential role played by the variable epitopes in
controlling HCV infections.
In the present work, a quantitative analysis of the HVR1 CR, modeled using synthetic peptides and mouse
immunization, in conjunction with a network analysis of the HVR1 sequence space showed significant immuno-
logical and structural HVR1 convergence. The findings suggest tractability of the HVR1immunological specificity,
and offer a novel framework for HCV vaccine development, which is applicable to other heterogeneous viruses.
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ConvergenceofHVR1CR.CRanalysisamongHVR1variantsusing
human serum specimens is complicated by the multi-specificity of
the humoral response against numerous HCV variants in a given
infected host. To overcome this problem, many groups have used
micetostudytheimmuneresponsetotheHVR1epitope
26–28.Several
studieshaveshownthespecificreactivityofHVR1peptideswithsera
of infected individuals
26,27,29–33. We modeled HVR1 CR using serum
specimens from mice immunized with 103 synthetic peptides
representing different HVR1 variants (referred to as immunogens).
A set of 261 HVR1 peptides was used as antigens in an enzyme
immunoassay, of which 102 sequences were also used as immuno-
gens. All HVR1 variants were randomly selected from major
branches of a phylogenetic tree constructed using sequences available
in GenBank. A total of 165,120 immunoassay reactions were evaluated.
Among 26,883 unique immunogen-antigen pairs, 5039 (18.7%) were
cross-immunoreactive (Fig. S1 and Table S1).
Many HVR1 variants derived from different genotypes were
found to be cross-immunoreactive (Fig. S2). The CR frequency
was 16.2% and 20.6% between inter- and intra-genotypic pairs,
respectively. This finding points to the independent occurrence
of the identical immunological specificity among phylogenetically
unrelatedvariants,indicatingtheexistence ofimmunological homo-
plasy. There was an inverse relationship between the Hamming dis-
tance and CR frequency among pairs of HVR1 variants (Fig. 1A).
Thus, the increase in genetic distance between viral variants was
associated with a decline in the capacity of antibody raised against
one variant torecognize another variant. However, this distance plot
(Fig. 1A) shows two intriguing findings. First, 12.4% of variants
differing from each other at 21–25 positions were cross-immunor-
eactive. Such an extreme difference in aa composition is another
strong indication of the independent origin of identical immuno-
logical specificities, which suggests convergence of the HVR1
immunological properties. Second, 18.4% of all tested variants did
not show self-immunoreactivity. Although most of these peptides
showed CR with others (ranging from 0% to 34.9%), the group of
immunogens that did not self-react showed a lower average CR level
than the group of immunogens that self-reacted (MRPP test
34;p5
0.0001).
The last observation suggests separation between immunogenic
andantigenic HVR1specificities under the experimental conditions.
This observation was further extended by analysis of the range of
antibody and peptide CR (Fig. 1B). The frequency distributions for
immunogens (median 8.8%) and antigens (median 18.4%) were dis-
tinctly different (Kolmogorov-Smirnov Test, p , 0.0001); 53.4% of
the immunogens reacted with ,10% of antigens, and only 2.9% of
immunogens showed broad immunoreactivity with .90% of pep-
tides, the maximum being 97.7% for HVR1 variant P240 (genotype
1a). These observations show a highly non-uniform CR distribution
among HVR1 immunogens. In contrast, the frequency distribution
ofantigenCRwascenteredattheaveragevalue.Noneoftheantigens
reacted with .52.5% of the immunogens (Fig. 1B). This difference
betweentheantigenandimmunogendistributionswasalsoreflected
in the identification of 2 minimal sets of peptides. One set (n53,
peptidesP032,P240andP247)collectivelyelicitedantibodiesimmu-
noreacting with all 261 antigens. The other set (n514) immunor-
eacted with antibodies against 101 out of 103 immunogens. The
observed separation between antigenic and immunogenic properties
may be explained by differences in conformational states of the con-
jugated peptides used for immunization and free peptides used for
antibody detection, indicating conformation dependence of the
HVR1 antigenic epitopes.
To further evaluate HVR1 CR, we constructed a network where
eachnodeisanHVR1sequenceandthereisalinkbetweentwonodes
if the reaction between the two corresponding peptides was positive
(Fig. 1C). All HVR1 sequences were connected in a single giant
component. Topological analysis showed that this network is a
‘‘small world’’
35 and has a small average shortest path between every
pair of reachable vertices (2.04 steps) and a small diameter (5 steps),
the maximum shortest path between two vertices. The network also
lacks identifiable modules or communities, suggesting an overall
homogeneity of the HVR1 immune recognition. These findings
emphasize the pervasive incidence of broad CR among HVR1 var-
iants.Toreducebiasthatmaybeintroducedowingtotheasymmetry
of this network composed of a different set of immunogens and
antigens, we extracted the symmetric subnetwork consisting only
of the 102 peptides which were both immunogens and antigens.
For this subnetwork, the average CR was 20%, and average shortest
path distance and diameter were 2.01 and 4, respectively, thus being
similar to the total network.
Figure 1 | A) Relationship between CR and genetic distance. The
Hamming distance is the number of different aa positions. B) CR
distribution. Percentage of peptides found in each CR bin. The numbers
below bins show the upper limit of the CR values. C) CR network. Each
node is an HVR1 sequence and there is a link between two nodes if the
reaction between the two peptides was positive.
www.nature.com/scientificreports
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of a peptide as immunogen and as antigen (Fig. S3). Moreover, only
11% of all links in the subnetwork were bidirectional, indicating that
the majority of peptides used in this study had different immuno-
genic and antigenic specificity. Nonetheless, it was still possible to
follow a path from a given variant to almost any other in a few steps,
with 89.3% of all possible pairs being reachable. We also calculated
the clustering coefficient
36, defined as the ratio between the number
oflinksoftheneighborsofanodeandthenumberoflinkstheycould
haveiftheywereafullyconnectedsubgraphorclique,wascalculated
for each node. The subnetwork had a high local structure with an
average clustering coefficient of 0.6658, such a high value being
related to the large number of cliques (n52,979) in the network.
Each clique contained 3–17 nodes (average of 12.72). A clique in
the network can be viewed as a set of variants sharing a single
immunological specificity.
Convergence of HVR1 sequence space. To study the structure of
HVR1 sequence space, we compiled 11,319 HVR1 sequences from
3,172patients.Thefulldatasetcontainedsequencesoftwoclasses:(i)
multiple clonal variants obtained from a single time-point from 176
patients, and from 2–14 time-points from 29 patients; (ii) a single
consensus sequence from 2,967 independent patients. Of all
sequences, 65.4% were obtained from the Los Alamos HCV
Sequence Database
37, and 34.6% were clonal variants generated in
our laboratory using end-point limiting-dilution PCR
38. The final
dataset included 4757 unique aa sequences: 3432 sequences of
genotype 1, 727 of genotype 2, 235 of genotype 3, 103 of genotype
4,75ofgenotype5,43ofgenotype6,and142ofunknowngenotypes.
When considering only epidemiologically unrelated sequences, the
percentageofsequencevariationduetodifferencesamonggenotypes
is4.7timeshigheratthenucleotidelevel(average20.76%)thanatthe
aa level (4.39%). Even though these average differences among
genotypes are statistically significant, the maximum likelihood
trees of nucleotide or aa sequences do not show clear genotype-
specific clusters (Fig. S4 and S5). The lack of genotype-specific
clustering is characteristic only for HVR1, since inclusion of the
flanking regions from E1 and/or E2 regions completely restores
phylogenetic relationships among HCV sequences.
Taking into consideration a potential convergence among HVR1 aa
sequences and the dimensionality problem (see Methods for details),
we have studied different ways of portraying this sequence space,
giving preference to approaches that could accurately model distances
among closely related sequences. The sequence space was visualized
using a Pathfinder network (PFNET) based on the entropy-weighted
Hamming distances between 4,757 unique HVR1 aa sequences
(Fig. 2A). Each unique aa sequence is represented with a node in
the PFNET and each link connects nodes of the highest similarity.
The low level of differentiation among genotypes at the aa level is
also evident in the lack of genotype-specific clusters in the PFNET
model of sequence space (Fig. 2A), which shows that HVR1
sequences from different HCV genotypes explore the same space
at the aa level. Only 3.15% of the variability in path distances among
epidemiologically unrelated sequences can be attributed to genotype
differences. A similar observation has been made for the two most
prevalentsubtypesinthePFNET,1aand1b.Thesefindingssuggesta
significant HVR1 convergence among HCV genotypes, with each
representing basically the entire HVR1 sequence space. Addi-
tionally, we measured the shortest path between any two sequences
over the entire PFNET. The diameter and the average shortest path
were calculated for populations of intra-host HVR1 variants from
(i)singletime-pointsattheacutestage,(ii)singletime-pointsduring
chronic infection, (iii) multiple time-points follow-up, and (iv) var-
iants of different genotypes. Both measures reflect the breadth of
distribution of variants in the PFNET. Although there was, in gen-
eral, a significant difference in both the diameter and average
Figure 2 | A) Location of HVR1 variants from 6 HCV genotypes in the
sequence space modeled with PFNET. Each genotype is shown in a
different color. B) Exploration of the PFNET by different HVR1 samples.
The acute group consists of 34 single time-point samples, the chronic
group has 90 single time-point samples, the follow-up group has 29
clusters and the genotype group consisted of 8 clusters. C) Exploration of
sequence space by HVR1 variants from 5 follow-up patients. Patient 1001
to 1004 were described in
50. Patient 7001 was described in
33.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 267 | DOI: 10.1038/srep00267 3distanceamongallfoursets(MRPP,p50.0001),anoverlapinthese
values was observed at different evolutionary levels (Fig. 2B). All
pair-wisecomparisonsofthediameterandaveragedistancebetween
sets were significantly different (Table S2), except between the
chronic and follow-up sets (MRPP, p 5 0.7305).
Although most of the single time-point samples had a small dia-
meter, some samples contained variants spreading in PFNET far
from each other and had a diameter greater than follow-up patients.
Anotherobservationwasthatvariantsfromsomechroniccaseswere
found so scattered in the PFNET that they had diameter and average
distance overlapping with the measures for some HCV genotypes,
thus indicating that HVR1 variants generated during intra-host
evolution in some patients may explore the HVR1 space at a scale
similar to subgenotypes and genotypes. Fig. 2C shows the range of
exploration of the PFNET sequence space by variants from five
patients who were followed-up for 8.8 to 26 years. HVR1 variants
from patient 1001 (genotype 1a) are represented with 540 sequences
collected over a period of 16.0 years at 13 time-points; from patient
1002 (1a) with 497 sequences collected over a period of 18.2 years at
14 time-points; from patient 1003 (1b) with 180 sequences collected
over a period of 8.8 years at 5 time-points; from patient 1004 (1a)
with 574 sequences collected over a period of 16.0 years at 10 time-
points;andfrompatient7001(1a)with52sequencescollectedovera
period of 26.0 years at 8 time-points. The variants from each of two
patients, 1001 and 7001, were found in different regions of the
PFNET. Collectively, all these observations suggest that the HVR1
space is small; it is entirely scanned by each genotype, and can be
widely traversed by intra-host HVR1 variants. However, although
the space is small for the independent accommodation of genotypes
and subgenotypes, it is sufficiently large to provide a significant
flexibility for the intra-host HVR1 evolution that would facilitate
HCV escape from the neutralizing immune responses.
CR Distribution in the HVR1 sequence space. All peptides used in
this study were mapped in the PFNET to show the uniform
distribution of the tested variants in the modeled sequence space
(Fig. 3A). The cross-immunoreactive pairs of sequences were
linked to visualize CR distribution in this network. Although this
visualization showed that CR occurred among widely scattered
peptides rather than being confined to some particular regions of
the network, the high density of links precluded the detection of
any meaningful structure in this distribution. Further analysis of
topological parameters of the PFNET showed that the closeness
centrality, measured as the average shortest path from a given
node to all other nodes in the network, is significantly associated
with the CR range of the peptides (Fig. 3B). The average CR of
immunogens with the highest centrality is 3.37 times greater than
for immunogens with the lowest centrality (MRPP, p 5 0.0099). A
similar, albeit less distinct, trend was observed for the antigens, with
an average CR that was 1.64 times greater for the most central than
for the least central (MRPP, p 5 0.0099). This observation suggests
that the HVR1 sequence space as modeled with PFNET is associated
with CR and, therefore, links HCV evolution with specific
immunological recognition of HVR1 epitopes.
Predictive model of HVR1 CR. The significant functional and
structural convergence observed in this study indicates that the
same HVR1 properties evolved frequently and independently in the
occupied sequence space. Such regular occurrence of the limited
number of immunological specificities renders them tractable and
highly amenable to predictive modeling. Therefore, we generated a
classification model in the form of a decision tree associating HVR1
sequenceandCR.ThissimplemodelpredictedCRbasedonsequence
of the immunogen and antigen pairs (Fig. S6). A 10-fold cross-
validation showed that the average testing accuracy was 92.5%
(S.D. 0.4%), with the average sensitivity and specificity being 99.7%
(S.D. 0.2%) and 85.3% (S.D. 0.7%), respectively. Using this model,
we predicted global cross-immunorectivity among all possible pairs
of sequences in the PFNET (n52.26E107). A strong inverse
relationship between the distance of two peptides and the predicted
CR frequency was found (Fig. 4A). Likewise, the distributions of
the predicted and observed cross-immunorectivity are similar both
for antigens and immunogens (Fig. 4B). Although most of the
immunogens had a low predicted breadth of immunoreactivity, we
found 73 sequences (1.53% of all analyzed) with predicted CR of .
99% in different parts of the PFNET (Fig. S7 and S8). These variants
may be viewed as highly cross-immunoreactive HVR1 mimotopes,
thereby supporting vaccine development strategies that rely on
discovery of broadly immunoreactive epitopes
12–14.
Since theexperimentally tested peptides represent asmall fraction
of all HVR1 sequences, they are substantially different from each
other and cannot be used to evaluate CR among very closely related
variants that may be expected at a single time-point in individual
patients.However,thepredicteddatacanbeusedtoassesssuchlocal
CR by calculating for each HVR1 variant the CR percentage to its 5
closestgeneticsequencesinthefullHVR1dataset(Fig.4C).LocalCR
Figure 3 | A) PFNET map of the experimentally tested HVR1 variants and
their CR. The sequences used as both immunogen and antigen are shown
in red (n5 103), the sequences used only as antigen are shows in blue
(n5261) and the sequence used only as immunogen is shown in purple
(n51).Thelightgreenlineslinkcross-immunoreactive variants.B)HVR1
CR peptides according to their PFNET centrality. All nodes were divided
into5binsstartingfrommost peripheral (left)tomostcentral (right).The
numbersbelowbinsshowtheupperlimitoftheclosenesscentralityvalues.
The standard error of the mean is shown as black bars.
www.nature.com/scientificreports
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are, the more likely they will cross-immunoreact. Although both
local and global CR distributions were similar for immunogens,
the antigen distributions were strikingly different, with the local
distribution being considerably skewed (Fig. 4C). However, most
HVR1 variants were predicted to be largely non-immunoreactive
witheachother(52.8%oftheimmunogensand39.3%oftheantigens
do not cross-immunoreact locally). This finding is consistent with
the suggested role of HVR1 in HCV escape from immune responses
during human infection
17–21.
The predicted CR was compared between aforementioned acutely
infected (34 patients, 130 unique aa sequences) and chronically
infected patients (90 patients, 799 unique aa sequences). The average
global CR was significantly lower (MRPP, p 5 0.0155) in the acutely
infected patients (average 5 10.60; S.E. 5 1.84) than in the chron-
ically infected patients (average 5 17.10; S.E. 5 1.46). This finding
is consistent with previous observations made for HCV-infected
patients
27,39. The data shown here suggest, however, that the lower
immunogenic CR in the acute-phase specimens is related to HVR1
properties and not only to the lower heterogeneity of intra-host
populations usually found in acutely infected patients. Additionally,
all these observations indicate that the predictive model captures
HVR1 CR not only under the specific experimental conditions but
also reflects some HVR1 immunological properties existing during
human HCV infections. Nevertheless, considering the conformation
dependence of the HVR1 CR (Fig. 1) discussed above, it should be
noted that the observed specificity of immunological reactions will
vary depending on the experimental conditions. A high accuracy of
the decision tree model (Fig.S5) indicates that the HVR1 structural
properties are strongly linked to specificity of immunoreactivity, sug-
gesting the use of such models to cope with HCV heterogeneity for
vaccine design. However, these models should be generated with
consideration of the experimental conditions and HVR1 presentation
in different protein contexts.
Discussion
Development of vaccines against HCV and other genetically hetero-
geneous viruses is hindered by lack of understanding of the factors
thatdefinetherelationshipbetweengeneticvariabilityandimmuno-
logical specificity of antigenic epitopes. Elucidation of CR among
variable antigenic epitopes is crucial for vaccine development. In
thepresentwork,wehavemodeledtheHVR1CRanditsdistribution
in sequence space, and formulated a novel concept of antigenic con-
vergence for highly heterogeneous antigenic epitopes.
CRamongHVR1variantshasbeenreadilyobservedinearlyHCV
experiments
22,26,29,30. Using well characterized antibodies, several
studiesconfirmedtheseearlyobservationsandshowedthattheCRis
most probably associated with the HVR1 structural constraints
26–28.
These findings prompted a search for natural variants
31 and mimo-
topes
13 with a broad HVR1 CR. However, these studies did not
succeed in establishing a quantitative association of CR to HVR1
heterogeneity. For example, Jackson et al
31 conducted an extensive
examination of CR (maximum531.1%; mean59.53%) among a
number of HVR1 peptides but found no firm connection of
immunological reactivity to sequence. Detection of CR (max-
imum583.3%; mean536.7%) among HVR1 variants derived from
different HCV genotypes
40,41 and the highly variable degree of
immunoreactivity of sera with peptides containing HVR1 variants
from the same patients
27,41 clearly illustrates the lack of a simple
association between sequence similarity and CR.
It must be noted that CR is essential but not sufficient for cross-
neutralization. Nevertheless, given that immune recognition is a
necessary step in viral neutralization, the modeling of CR among
highly variable antigenic epitopes constitutes a critical starting point
toward overcoming genetic diversity for development of an effi-
caciousHCVvaccine.Here,wemadeseveralimportantobservations
useful for harnessing CR. First, the HCV HVR1 sequence space was
found to be explored in its entirety by different HCV genotypes and
subtypes, thus indicating a smaller size of the space than can be
expected from the number of existing HCV strains. Also, it supports
theuseofHVR1sequencevariantsfromasinglesubtypeorgenotype
for vaccine development. Second, in agreement with previous stud-
ies, we found a broad CR among genetically distant HVR1 variants,
including variants from different HCV genotypes
40,41. The skewed
CR distribution implies that many HVR1 variants act as natural
mimotopes.Weshowedthatantibodies againstafewHVR1variants
were immunoreactive with all tested peptides. Thus, in addition to
thesequencespace limitations, thenumber ofHVR1 immunological
specificities is also lower than can be expected from the number of
HCV strains. The findings support vaccine development strategies
thatrelyondiscoveryofbroadlycross-immunoreactiveepitopes
12–14.
Third, predictive models generated in this study showed for the first
time that the HVR1 CR can be predicted based on sequence alone
and there is a strong association between CR and HVR1 structure.
Such in silico models should significantly facilitate a rational
exploitation of HVR1 CR for vaccine development. Fourth, the gen-
eral separation between antigenic and immunogenic properties sug-
gests that selection of antigens for vaccine development should not
Figure 4 | A) Relationship between predicted CR and hamming distance.
B) Predicted global CR distribution among 4,757 HVR1 variants. The
average global CR of the immunogenes is 18.1% (S.E. 5 0.3) and of
antigens is 18.1% (S.E. 5 0.1). C) Predicted local CR distribution among
4,757 HVR1 variants. The average local CR of the immunogenes is 27.4%
(S.E. 5 0.5) and of antigens is 28.6% (S.E. 5 0.5).
www.nature.com/scientificreports
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reactivity; rather, immunogenic reactivity should be assessed. Fifth,
the observed immunological convergence is defined by the strong
conformational dependence of HVR1 epitopes, implying that the
specificity of HVR1 CR may vary depending on the model system
used for epitope presentation. Therefore, translation of the specific
CR results from a model, for example based on synthetic peptides
and mice immunization, to human vaccine development must be
carefully approached. The HVR1 CR should be modeled at condi-
tions approximating the actual vaccine application.
Although all observations of CR have been made in this study
using a model system of synthetic peptides and mouse immuniza-
tion, antigenic convergence is most probably a common property of
highly heterogeneous antigenic epitopes. This conclusion is strongly
supported by the recently reported identification of the specific anti-
genic reactivity among 10,000 random-sequence peptides to all
tested antibodies
42,43. The observations of the statistically significant
association between CR frequency and sequence space centrality, or
thestageofHCVinfectionasdescribedinthispaperstronglysuggest
that the model presented here captured a general distribution of
immunological specificities among HVR1 variants.
It is commonly expected that CR rapidly declines with increasing
genetic difference between epitopes. This assumption taken in the
context of the expanding viral sequence space shaped by diversifying
evolution is generally considered as a basis for immune escape and
provides the major framework for vaccine development against highly
heterogeneous viruses. The data obtained in this study indicate that
this assumption is strongly consistent with the CR observed among
closely related HVR1 variants usually found in each infected patient.
However, frequent CR among genetically distant HVR1 variants sig-
nificantly reduces the inverserelationship between thegenetic distance
and CR (Fig. 1A), indicating that the number of immunological spe-
cificities distributed across the entire HVR1 sequence space is limited.
This restriction has different bearing on the intra- and inter-host
evolution. The sequence space available to each HCV variant provides
ample opportunities for the successful intra-host HVR1 evolution,
facilitating immune escape during chronic infection. However, the
HVR1 convergence significantly limits inter-host HCV evolution.
This reduction in the genetic and immunological HCV diversity pre-
sents a different prospect on vaccine development than the concept of
continues diversifying viral evolution.
The HCV HVR1 convergence observed in this study should be
viewed as the natural extension of diversifying evolution that occurs
in a limited sequence space. Owing to strong structural and functional
constraints
16,44–46, the HVR1 sequence space is severely restricted in
size. The expansion under recurring selection pressures can result in
‘‘exhaustion’’ofthe limited sequence space so generating conditionsfor
frequent occurrences of homoplasy
47. The data obtained here suggest
that extensive convergence is a principal factor affecting the distri-
bution of immunological properties among HVR1 variants. As a result,
identical immunological specificities are repeatedly being observed
among genetically distant variants, contributing to widespread epitope
mimicry in the HVR1 sequence space. In contrast to diversification,
convergence makes HVR1 variability tractable. Thus, the homoplastic
nature of the HVR1 diversity turns the extensive genetic variability
from drawback to opportunity, and offers a novel and more general
framework for development of a viable hepatitis C vaccine.
The interaction between virus and host is frequently compared to
an‘‘armsrace’’
16,anidearootedindiversifyingviralevolutiondriven
by antagonistic relationships with the host. Although such a process
might explain viral escape from host immune responses, it is not
instructiveforvaccinedevelopment.Agameofchessisamoreuseful
metaphor describing HCV evolution. The chessboard symbolizes a
limitedintra-hostphenotypic spaceavailable toHCV,whichiscom-
posedofcharacterstates(immunologicalspecificities)representedas
squares. Each square may be occupied by different figures (genetic
variants), resulting in homoplasy. HCV frequently cheats, making
several mutation-moves at once, and rapidly traversing across the
entire space-board, a strategy that results in persistent infection.
With a very similar ‘‘game’’ played during each infection, conver-
gence is ingrained in HCV evolution.
Focus on sequence differences rather than on shared characteris-
tics among viral variants hinders the discovery of phenotypic con-
vergence. Convergent patterns of HCV immune responses pave the
wayfornewpreventionstrategiesthatexploitthehomoplasticnature
of HCV sequence space. The concepts of convergence and tractabil-
ity of diverse immunological specificities presented here should be
applicable to other genetically heterogeneous viruses such as HIV
andinfluenzavirus,socontributingtotherationaldesignofvaccines
against these infections.
Methods
Synthetic peptides. A set of 262 HVR1 sequences was selected from Genbank
sequences as described in Results, with 192 sequences belonging to genotype 1, 26 to
genotype 2, 35 to genotype 3, 2 to genotype 4, 1 to genotype 5 and 6 to genotype 6. A
control set of 29 synthetic peptides derived from proteins encoded by unrelated
hepatitis delta virus and hepatitis G virus. These irrelevant peptides of different sizes
were used as negative controls accounting for non-specific immunoreactivity of
mouse serum specimens in all enzyme immunoassay experiments. All peptides were
synthesized using standard f-moc chemistry. Quality control of the peptides was
performed by Matrix-assisted laser desorption/ionization-time-of-flight (MALDI-
TOF) mass spectrometry and high-performance liquid chromatography (HPLC).All
peptides used in these experiments were similar in their quality.
Immunization of mice. For immunization of mice with synthetic peptides, 103
HVR1 peptides were first conjugated with BSA as a carrier protein. Each conjugated
peptide wasdiluted with 13 PBS toa final concentration of1 mg/ml and mixed with
an equal volume of the adjuvant TiterMax (CytRx Corp, Norcross, GA). Each group
of three 4–6 week-old female Balb-C mice was injected intraperitoneally with 100 ml
of the resulting emulsion (50 mg of peptide) containing a single BSA-conjugated
HVR1peptide.Twoweeksafterfirstinjection,aboosterwasadministered with50mg
BSA-conjugated peptide (without adjuvant). Two weeks after booster mice were bled
and serum specimens were obtained.
Enzyme immunoassay (EIA). Synthetic peptides representing 261 HVR1 variant
sequences of 31 aa in length obtained from GenBank and 29 unrelated peptides were
used as antigens in the assay. Wells of 384-well high binding plates were coated with
0.25 mg HVR1 peptides in a volume of 25 ml/well in PBS overnight at RT. Each well
was coated with a different peptide and 16 wells were coated with 1.25 mg BSA as a
controlonimmunoreactivity.Afterincubation,wellswerewashedfivetimeswith100
ml PBS/0.05% Tween 20 (PBST) and 25ml of serum diluted 15400 in PBST/10%
normal goat serum (NGS) was added. After incubating the plates at 37uC for 90 min,
wells were washed again five times with PBST and 25 ml horseradish peroxidase-
labeled anti-mouse IgG antibody diluted 1550,000 in PBST/10% NGS was added to
each well. After washing five times with PBST, 25 ml of 1-Step Ultra TMB-ELISA was
added for color development for 30 min at RT, followed by 25 ml2 MH 2SO4 to stop
the reaction and plates were read at OD450.
Negative controls. The reproducibility of experimental conditions between tests
conducted at the same day or at different days is very important for accurate
mathematical modeling of results. To control for inter-plate variation in each
experiment, each 384-well plate contained 16 BSA-coated wells, 8 of which were
tested against a 1530,000 dilution of pool of mice sera immunized with BSA and 8
were tested against a 1515,000 dilution. The inter-plate variation was low (S.D.
5.47%). The reactivity between serum and peptide was considered positive if it
showed a signal/cut-off value .1 calculated for two types of negative controls.
(i) Negative controls A: A cut-off was calculated for each peptide, based on its
reactivity with 35 sera obtained from mice each immunized with different
irrelevant peptides conjugated to BSA using the protocol described above.
Cut-off value was calculated as the average of negative controls plus 3.5 times
of the standard deviation. The average cut-off for all peptides was 0.07547.
(ii) Negative control B: A cut-off was calculated for each serum, based on its
reactivity with 29 different unrelated peptides. Cut-off value was calculated
astheaverageofnegativecontrolsplus3.5timesofthestandarddeviation.The
average cut-off for all sera was 0.08567.
The reactivity of each immunogen and antigen pair was scored as 1 if one or more
of the 3 immunized mice showed a positive reaction. Supplementary figure S1A
shows the number of mice with a positive reaction between each tested immunogen
and antigen. The percentage of cross-immunoreactive reactions with one or more
mice is 18.74%, with two or more mice is 7.09% and with three mice is 2.43%. The
average agreement between mice immunized with the same BSA-conjugated peptide
was 88.78 (S.D. 14.98).
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vertex is a HVR1 sequence and there is a link between two nodes if the reaction
between the two peptides was positive. Several topological measures of this network
were calculated using the PAJEK software
48. The CR network is difficult to visualize
due to its high density of links, therefore, we used the k-shell decomposition method
to disentangle the hierarchical structure of the network
49.
Minimal cover set. The smallest set of immunogens that can have positive reactions
with the whole set of antigens was considered as the minimal cover set. This set is a
binary integer optimization problem, which was solved using a linear programming
(LP)-based branch-and-bound algorithm implemented in MATLAB (MathWorks,
Natick, MA).
Data from acute and chronic samples. For the determination of diameter and CR
differences between acute and chronic stages of HCV, two groups of samples were
used: (A) the acute group included 130 different aa sequences from 34 single time-
pointsamples
33,50,51,52;(B)thechronicgroupincluded799differentaasequencesfrom
90 single time-point samples tested in our laboratory
53.
Sequence space model. The whole dataset contained sequences of two classes: (A)
multiple clone variants obtained in our laboratory from single time-point samples
from 176 patients using the end-point limited-dilution (EPLD) real-time PCR
38 and
obtainedfrompublished dataon23samples
51;andmultipleclonesobtainedfromthe
follow-up specimens (2–14 time-points) from 29 patients
50,52,54,33; and (B) sequences
obtained by consensus sequencing from 2967 unrelated patients, which were
recovered from the Los Alamos HCV Sequence Database
37 during early 2008.
Recombinant and chimeric sequences as well as patented sequences and sequences
obtained from non-human hosts were excluded from analysis.
All sequences can be viewed as points in an informational space known as Sequence
space. We have studied different ways of portraying this sequence space, taking into
consideration two important problems: aa convergence and the dimensionality curse.
(i) aa convergence: different aa could have very similar physicochemical properties or
fulfill the same functionin this particular segment and, therefore,itis desirabletobuild
a sequence space that takes into account these differences. For HVR1, we assume that
some positions are less variable because changes affect more its structure and function
than changes in highly variable positions. The entropy of each aa position was calcu-
lated for the whole dataset and these entropy values were used to create weights in the
calculation of the Hamming distances between every pair of sequences. (ii)
Dimensionality curse: One of the most important goals in visualizing data is to get a
sense of how near or far points are from each other. However, as dimensionality
increases, the distance from a given point to the nearest point approaches the distance
to the farthest point
55. Distances in sequence space lose discriminatory power very
rapidly. Accordingly, analysis was focused on the accurate portrayal of local relation-
ships. We have created a model of sequence space using PFNET
56, which in essence
prunes a dense network. PFNETs have the ability to derive more accurate local
structuresthanotheralgorithmswherethe resultingrelationships between neighboring
points are often significantly different from the original data
56. The network generation
procedure incorporatestwo parameters: (1) the r parameter defines the metric used for
computing the distanceof paths. (2) the q parameterconstrains the numberof indirect
proximities examined in generating the network. The network with the minimum
number of links is obtained when q 5 n21a n dr5 ‘, i.e., PFNET(n21,‘).
Analysis of molecular variance (AMOVA). Each genotype was considered a
subpopulationofthe HVR1sequence spaceand distances among these subpopulations
were further explored by AMOVA as implemented in ARLEQUIN
57. The genetic
structure was analyzed with consideration of the molecular differences between
sequences in addition to differences in their frequencies. Different types of distances
were used: The nucleotide Hamming, aa Hamming and path distance (the number of
steps in the shortest path connecting the pair of peptides in the PFNET). Significance
levels of the variance components were estimated after 10,000 permutations.
Multi-response Permutation Procedure (MRPP). MRPP is a non-parametric
permutation test for testing the hypothesis of no difference between two or more
groups of entities
34, as implemented in the program BLOSSOM
58. The distribution of
values under the null hypothesis of no difference between groups was obtained by
permutating the grouping labels (n510,000).
Ethics Statement. (i) Mice experiments: This study was carried out in strict
accordance with the recommendations of the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Protocols for mouse
immunization experiments have been approved by the Centers for Disease Control
and Prevention Animal Care and Use Committee (1403KHUMOUC). All efforts
were made to minimize suffering. (ii) Human subjects: Blood specimens of 4 follow-
up patients were acquired with written informed consent and all research involving
human participants were approved by the institutional review board (Centers for
Disease Control and Prevention, IRB#1428). Description of the NHANES III study
can be found in
53. Clinical investigations have been conducted according to the
principles expressed in the Declaration of Helsinki.
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